Breakthroughs and challenges in the management of tropomyosin receptor kinase fusion-positive tumors

被引：0
|
作者：
Mamdani, Hirva [1 ]
Jalal, Shadia I. [2 ]
机构：
[1] Wayne State Univ, Karmanos Canc Inst, 4100 John R, Detroit, MI 48201 USA
[2] Indiana Univ, Melvin & Bren Simon Canc Ctr, Indianapolis, IN 46204 USA
来源：
ANNALS OF TRANSLATIONAL MEDICINE | 2019年 / 7卷
关键词：
TRK; ENTRECTINIB; INHIBITOR; ONCOGENE; ROS1;
D O I：
10.21037/atm.2019.06.41
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页数：4
相关论文
共 50 条
  • [21] The Use of Zenocutuzumab for NRG1 Fusion-Positive Tumors
    Schram, Alison
    CLINICAL ADVANCES IN HEMATOLOGY & ONCOLOGY, 2024, 22 (10) : 487 - 489
  • [22] LONG-TERM EFFICACY AND SAFETY OF LAROTRECTINIB IN PAEDIATRIC PATIENTS WITH TROPOMYOSIN RECEPTOR KINASE (TRK) FUSION-POSITIVE PRIMARY CENTRAL NERVOUS SYSTEM (CNS) TUMOURS
    Nysom, Karsten
    Doz, Francois
    Geoerger, Birgit
    Ora, Ingrid
    Perreault, Sebastien
    Norenberg, Ricarda
    Fellous, Marc
    De La Cuesta, Esther
    Laetsch, Theodore W.
    van Tilburg, Cornelis M.
    NEURO-ONCOLOGY, 2022, 24 : 64 - 64
  • [23] ROLE OF CYCLIN DEPENDENT KINASE 8 IN FUSION-POSITIVE RHABDOMYOSARCOMA
    Just, Marissa
    Oristian, Kristianne
    Kovach, Alexander
    Linardic, Corinne
    PEDIATRIC BLOOD & CANCER, 2021, 68 : S4 - S5
  • [24] Impact of disease evolution on efficacy outcomes from larotrectinib in an ad hoc pooled analysis of patients (Pts) with locally Advanced or Metastatic (Adv/Met) Tropomyosin Receptor Kinase (TRK) fusion-positive solid tumors
    Bokemeyer, C.
    Vassal, G.
    Italiano, A.
    De La Cuesta, E.
    Hiemeyer, F.
    Fellous, M.
    Marian, M.
    ONCOLOGY RESEARCH AND TREATMENT, 2020, 43 (SUPPL 4) : 250 - 251
  • [25] Tropomyosin receptor kinase inhibitors in the management of sarcomas
    Wilding, Christopher P.
    Loong, Herbert H.
    Huang, Paul H.
    Jones, Robin L.
    CURRENT OPINION IN ONCOLOGY, 2020, 32 (04) : 307 - 313
  • [26] The First Reported Case of Neurotrophic Tyrosine Receptor Kinase Fusion-Positive Thymoma Treated Successfully With Entrectinib
    Salame, Hassan
    Mckey, Remy
    Ballout, Mohamad
    Saad, Wajih
    CUREUS JOURNAL OF MEDICAL SCIENCE, 2021, 13 (12)
  • [27] Prevalence of neurotrophic tropomyosin receptor kinase (NTRK) fusion gene positivity in patients with solid tumors in Japan
    Nakata, Eiji
    Osone, Tatsunori
    Ogawa, Toru
    Taguchi, Tomoyuki
    Hattori, Kana
    Kohsaka, Shinji
    CANCER MEDICINE, 2024, 13 (12):
  • [28] Utility of NTRK RNA In Situ Hybridization in NTRK Fusion-Positive Tumors
    Boyraz, Baris
    Neyaz, Azfar
    Hornick, Jason
    Chebib, Ivan
    Deshpande, Vikram
    MODERN PATHOLOGY, 2020, 33 (SUPPL 2) : 817 - 818
  • [29] Utility of NTRK RNA In Situ Hybridization in NTRK Fusion-Positive Tumors
    Boyraz, Baris
    Neyaz, Azfar
    Hornick, Jason
    Chebib, Ivan
    Deshpande, Vikram
    LABORATORY INVESTIGATION, 2020, 100 (SUPPL 1) : 817 - 818
  • [30] Larotrectinib Demonstrates CNS Efficacy in TRK Fusion-Positive Solid Tumors
    Rosen, Ezra Y.
    Schram, Alison M.
    Young, Robert J.
    Schreyer, Mark W.
    Hechtman, Jaclyn F.
    Shu, Catherine A.
    Ku, Nora C.
    Hyman, David M.
    Drilon, Alexander
    JCO PRECISION ONCOLOGY, 2019, 3 : 1 - 5
12345